Mach7 Technologies Ltd. (AU:M7T)
ASX:M7T
Want to see AU:M7T full AI Analyst Report?
Top Page
Mach7 Technologies
(Sydney:M7T)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.29
▼(-48.93% Downside)
Action:ReiteratedDate:04/01/26
The score is primarily held back by weak profitability and uneven cash flow despite strong revenue growth, alongside bearish-to-mixed technical signals (below key longer-term moving averages and negative MACD). Valuation is also pressured by losses (negative P/E) and no dividend support.
Positive Factors
Enterprise imaging focus
A focused enterprise imaging product set targets hospitals and health systems with complex, high-value workflows. Durable demand for imaging interoperability and cross-department integration makes the business sticky, supporting long-term contract opportunities and high switching costs.
Negative Factors
Negative profitability
Persistent negative net and EBIT margins indicate the business has not yet achieved sustainable unit economics. Over the medium term this limits free cash generation, reduces reinvestment capacity, and means profitability must improve materially to justify continued growth investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Enterprise imaging focus
A focused enterprise imaging product set targets hospitals and health systems with complex, high-value workflows. Durable demand for imaging interoperability and cross-department integration makes the business sticky, supporting long-term contract opportunities and high switching costs.
Read all positive factors
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$66.39M
Dividend YieldN/A
Average Volume (3M)368.13K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth15.99%
EPS Growth22.05%
CountryAU
Employees58
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding235,009,720
10 Day Avg. Volume349,234
30 Day Avg. Volume368,134
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)1.74
Price to Sales (P/S)2.35
P/FCF Ratio701.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.76Price Target Upside35.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$34.50M
Mach7 Technologies Business Overview & Revenue Model
Company Description
Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises in North America, the Asia Pacific, the Middle East, Europe and internationally. The company offers enterprise diagnostic...
How the Company Makes Money
Mach7 Technologies makes money primarily by selling enterprise imaging software to healthcare provider organizations (e.g., hospitals and health systems). Revenue is typically generated from (1) software license fees and/or subscription arrangemen...
Mach7 Technologies Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 02, 2026
Earnings Call Sentiment Positive
The call communicated a constructive operational pivot: management presented a clear strategic reset, measurable cost reductions (payments down 9% YoY, 6% QoQ), stronger cash flow (positive operating cash flow in Q2), a stable ARR run rate of $23M, and early commercial/product milestones (first Flamingo customer, CE certificate). These positives are tempered by a near-term reduction in CARR of $2.9M (removal of the NTP project), the strategic exit from the VHA program that reduced backlog but improves long-term margin prospects, lingering VNA/KLAS performance work that may take 12–24 months to fully resolve, and a CTO search following the CIO departure. Overall, the highlights (stabilized ARR, improved cash and cost discipline, new product momentum and regulatory/market expansion) outweigh the lowlights, although several improvements will take time to flow through revenue.Positive Updates
Stable ARR Run Rate
Annual recurring revenue (ARR) run rate remained steady at $23.0M on a constant currency basis, indicating resilience in subscription and maintenance revenue.
Negative Updates
Decline in Contracted ARR (CARR)
Total contracted annual recurring revenue (CARR) closed at $26.1M, representing a net reduction of $2.9M over the quarter, primarily due to the removal of the NTP project from the CARR backlog.
Read all updates
Q2-2026 Updates
Positive
Negative
Stable ARR Run Rate
Annual recurring revenue (ARR) run rate remained steady at $23.0M on a constant currency basis, indicating resilience in subscription and maintenance revenue.
Read all positive updates
Company Guidance
The guidance from the call emphasized steady fundamentals and disciplined execution: ARR run rate was stable at $23.0M (constant currency) with total CARR at $26.1M (a $2.9M net reduction driven primarily by removal of the NTP project); Q2 sales orders were $6.8M (including $3.1M of new sales), with renewals ≈40% ($2.9M) and add‑ons/expansions ≈$0.9M (≈14%); operating cash receipts were $7.9M and total cash payments were $7.9M (payments down 9% YoY and 6% QoQ), advertising/marketing spend was $0.4M, and the company finished the quarter with $18.5M cash and zero debt; management expects Flamingo-related opportunities to begin contributing meaningfully to ARR in H2 FY‑26 and into FY‑27, KLAS and ARR benefits to materialize over roughly 12–24 months given 1–2 year sales cycles, and continued cost and efficiency gains from organizational reshaping, Asia hiring (including a Malaysia developer and interns) and partner leverage (over a dozen partner engagements).Mach7 Technologies Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.70M | 33.79M | 17.24M | 30.06M | 27.08M | 19.03M |
| Gross Profit | 1.53M | 8.38M | -6.42M | 9.35M | -2.57M | -7.73M |
| EBITDA | -6.48M | -7.06M | -15.09M | 2.09M | 2.80M | -1.83M |
| Net Income | -10.08M | -6.20M | -7.97M | -1.05M | -4.17M | -9.36M |
Balance Sheet | ||||||
| Total Assets | 54.04M | 64.21M | 73.03M | 82.31M | 78.92M | 76.97M |
| Cash, Cash Equivalents and Short-Term Investments | 18.49M | 23.07M | 26.18M | 23.39M | 25.75M | 18.36M |
| Total Debt | 1.75M | 1.12M | 1.27M | 1.20M | 1.33M | 1.08M |
| Total Liabilities | 15.09M | 18.63M | 21.17M | 22.82M | 20.55M | 19.05M |
| Stockholders Equity | 38.95M | 45.58M | 51.86M | 59.48M | 58.38M | 57.91M |
Cash Flow | ||||||
| Free Cash Flow | -576.28K | 112.92K | 3.30M | -2.97M | 5.94M | 1.40M |
| Operating Cash Flow | -310.91K | 868.59K | 3.45M | -2.61M | 6.37M | 1.50M |
| Investing Cash Flow | -1.08M | -1.70M | -391.31K | -361.01K | -438.56K | -42.33M |
| Financing Cash Flow | -2.46M | -2.43M | -32.08K | -68.63K | 547.61K | 11.21M |
Mach7 Technologies Technical Analysis
Negative
0.56
Price Trends
0.32
Negative
0.42
Negative
0.37
Negative
Market Momentum
>-0.01
Negative
43.64
Neutral
15.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:M7T, the sentiment is Negative. The current price of 0.56 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.32, and above the 200-day MA of 0.37, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.64 is Neutral, neither overbought nor oversold. The STOCH value of 15.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:M7T.
Mach7 Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | AU$14.36B | 33.69 | 72.67% | 0.24% | 31.88% | 39.10% | |
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 10.06% | ― | |
54 Neutral | AU$679.15M | -13.78 | -35.63% | ― | ― | 0.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$145.77M | -13.72 | -226.75% | ― | 21.56% | -24.08% | |
47 Neutral | AU$66.39M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
44 Neutral | AU$45.05M | -5.70 | -14.19% | ― | 3.61% | -17.03% |
* Healthcare Sector Average
AU:M7T
Mach7 Technologies
0.29
-0.04
-12.12%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.18
-0.07
-28.00%
AU:PME
Pro Medicus Limited
148.74
-57.65
-27.93%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.06
-27.50%
AU:AYA
Artrya Limited
4.10
3.53
619.30%
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
Mach7 Technologies Corporate Events
Mach7 Director Increases Shareholding Through On‑Market Purchases
Apr 1, 2026
Mach7 Technologies has disclosed a change in the shareholding of director Teri Jo Thomas, who increased her direct holding in the company through on-market purchases. Thomas acquired a total of 50,122 fully paid ordinary shares in two transactions...
Mach7 Director Eliot Siegel Boosts Equity Stake Through On-Market Share Purchases
Apr 1, 2026
Mach7 Technologies has disclosed a change in director Eliot Siegel’s holdings, after he acquired additional fully paid ordinary shares through on-market purchases over two consecutive days at prices of $0.29 and $0.32 per share. Following th...
Mach7 Director Bazzani Increases Indirect Shareholding via On-Market Buys
Mar 30, 2026
Mach7 Technologies has disclosed a change in the holdings of director Robert Bazzani, detailing an increase in his indirect interest in the company’s fully paid ordinary shares. The additional shares were acquired through on-market purchases...
Mach7 Technologies Updates Market on Lapse of 100,000 Options
Mar 30, 2026
Mach7 Technologies has notified the market of the cessation of a total of 100,000 options with the ASX code M7TAJ, which were due to expire on various dates and at various exercise prices. The options lapsed in two tranches on 19 March and 29 Marc...
Mach7 Technologies Announces Lapse of 133,335 Conditional Options
Mar 10, 2026
Mach7 Technologies has notified the market of the lapse and cessation of 133,335 options that were subject to conditional rights over its securities. These options, which expired at various dates and exercise prices, ceased on 17 February 2026 and...
Mach7 Technologies Completes AUD 2.24 Million On‑Market Share Buy‑Back
Mar 3, 2026
Mach7 Technologies Limited has completed an on‑market share buy‑back of its ordinary fully paid shares on the ASX, repurchasing a total of 6,273,000 securities. The program, which was initially notified to the market in January 2025 an...
Mach7 Wraps Up Scaled-Back On-Market Share Buy-Back
Mar 3, 2026
Mach7 Technologies has completed its on-market share buy-back program, which ran from late January 2025 to early March 2026 and was originally authorised for purchases of up to $5 million in fully paid ordinary shares. The company ultimately repur...
Mach7 Technologies Reports Lapse of 90,000 Conditional Options
Mar 1, 2026
Mach7 Technologies has notified the market of the lapse of 90,000 options, originally exercisable at $0.98 and due to expire on 31 August 2026, after the specific conditions attached to these rights were not met or became incapable of being satisf...
Mach7 Sets Vision Around Global Imaging EMR in H1 FY26 Update
Feb 27, 2026
Mach7 Technologies has outlined its vision in conjunction with its H1 FY26 results presentation, positioning itself as a provider of a global imaging electronic medical record. By aiming to complete the patient picture with imaging data integrated...
Mach7 Resets Strategy as Profitability Slips on Lower Licence Sales
Feb 26, 2026
Mach7 Technologies reported first-half FY26 revenue of A$13.7 million, down 23% year on year, as fewer one-off capital software licence deals and some customer churn weighed on results despite recurring revenue rising to 85% of total. Operating ex...
Mach7 Technologies Reports Lapse of Conditional Options
Feb 22, 2026
Mach7 Technologies has notified the market of the lapse of 91,666 options with various expiry dates and prices, and 75,000 options expiring on 31 August 2026 at an exercise price of $0.98. The options have ceased because the conditions attached to...
Mach7 Technologies trims potential dilution as 433,334 options lapse
Feb 11, 2026
Mach7 Technologies Limited has notified the market of the cessation of certain options on issue, with a total of 433,334 options (ASX code M7TAJ) lapsing after the conditions attached to these rights were not met or became incapable of being satis...
Mach7 to Unveil H1 FY26 Results with Investor Webinar
Feb 10, 2026
Mach7 Technologies will release its H1 FY26 results for the six months to 31 December 2025 on 27 February 2026 and will host an investor webinar the same day, led by CEO Teri Thomas and CFO Dan Lee. The event, which will be recorded and made avail...
Mach7 Turns Cash-Flow Positive as Flamingo Launch Offsets VHA Setback
Jan 29, 2026
Mach7 Technologies reported a positive operating cash flow in the second quarter of FY26 and maintained a strong debt-free balance sheet with A$18.5 million in cash, as it advances a strategic reset aimed at sustainable, profitable growth. Quarter...
Mach7 Technologies Announces Lapse of 308,333 Options, Trimming Potential Dilution
Jan 27, 2026
Mach7 Technologies has notified the market that a total of 308,333 options (ASX code M7TAJ), which were exercisable at various prices and on various dates, have lapsed after the conditions attached to these rights were not met or became incapable ...
Mach7 Hit by VHA Program Halt but Reaffirms Commercial Growth Focus
Jan 23, 2026
Mach7 Technologies has confirmed that the U.S. Veterans Health Administration will halt its NextGen PACS program for the National Teleradiology Program, resulting in the termination of the multi‑vendor project in which Mach7 was a subcontrac...
Mach7 Technologies Sets Date for Q2 FY26 Results and Investor Webinar
Jan 21, 2026
Mach7 Technologies will release its Q2 FY26 results for the quarter ended 31 December 2025 on 30 January 2026 and will follow the announcement with an investor webinar hosted by CEO Teri Thomas and CFO Dan Lee. The session, open to the investment ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.